TIZA-Q 10 MG/0.5 ML PFS INJECTION

Dosage

Children: Refer to specific drug information for detailed dosage recommendations.

Adults: Refer to specific drug information for detailed dosage recommendations.

Mechanism of action

The mechanism of action varies depending on the specific drug that 'contains' certain active ingredients. Each compound will have its own unique pharmacological pathway and target within the body, which can include receptor modulation, enzyme inhibition, or other biochemical interactions.

Pharmacodynamics

Pharmacodynamics will depend on the active ingredients in the formulation. It generally encompasses the biochemical and physiological effects of the drug and its mechanisms of action, including the relationship between drug concentration and effect.

Pharmacokinetics

Pharmacokinetics involves the absorption, distribution, metabolism, and excretion of the specific active ingredients within the formulation. This can vary significantly based on the drug's chemical properties, route of administration, and individual patient factors.

Pregnancy

Consult with a healthcare provider before use, as safety during pregnancy has not been established.

Breast-feeding

Consult with a healthcare provider before use, as it is not known if this drug is excreted in human milk.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Administration of medications
• Vaccination
• Blood sampling
• Intravenous fluid delivery
• Intramuscular injection
• Subcutaneous injection

Dosage

Children: Refer to specific medication guidelines for dosing.

Adults: Refer to specific medication guidelines for dosing.

Mechanism of action

The syringe itself does not have a pharmacological mechanism of action, as it is a delivery system rather than a drug. Its function is to create a vacuum that allows for the drawing in or expulsion of fluids, relying on the movement of the plunger within the barrel to generate pressure differences.

Pharmacodynamics

As a non-pharmacological device, the pharmacodynamics of a syringe do not apply directly. However, the effectiveness of medications administered via syringe depends on the drug's own pharmacodynamics, which include the interactions with receptors, the onset of action, and the therapeutic effects of the drug delivered.

Pharmacokinetics

The pharmacokinetics of a syringe are not applicable, as it is a mechanical device. However, the pharmacokinetics of the medication administered through the syringe would include absorption, distribution, metabolism, and excretion, which are influenced by the route of administration (e.g., intravenous, intramuscular, subcutaneous).

Pregnancy

Syringes are generally safe for use during pregnancy when necessary for medication administration.

Breast-feeding

Syringes can be used during breastfeeding for medication administration without adverse effects.

Storage

Store syringes in a clean, dry place. Follow specific guidelines for pre-filled syringes or those with medications.

Formulations

• plastic syringes
• glass syringes
• pre-filled syringes
• safety syringes

Indications

• Type 2 diabetes mellitus
• Diabetes management in adults

Dosage

Children: Refer to the BNF for Children for any paediatric dosing recommendations.

Adults: Refer to the BNF for specific dosing guidelines based on individual patient needs and treatment response.

Mechanism of action

Tirzepatide works by mimicking the action of two incretin hormones, GLP-1 and GIP. Incretins play a crucial role in glucose metabolism by enhancing insulin secretion from the pancreas in a glucose-dependent manner, inhibiting glucagon release, and promoting satiety. The activation of the GLP-1 receptor leads to increased cAMP levels, improved insulin sensitivity, and decreased appetite. By also activating the GIP receptor, tirzepatide further amplifies the insulinotropic effect, contributing to improved glycemic control.

Pharmacodynamics

Tirzepatide's pharmacodynamic profile includes significant reductions in HbA1c levels and body weight in individuals with type 2 diabetes. Its dual receptor activation is associated with enhanced postprandial insulin secretion and reduced fasting and postprandial glucose levels. The effects are dose-dependent and can lead to substantial improvements in glycemic control over time.

Pharmacokinetics

Tirzepatide is administered via subcutaneous injection, with a peak plasma concentration occurring approximately 24 to 72 hours post-dose. It has a half-life of approximately 5 days, allowing for once-weekly dosing. The drug undergoes proteolytic degradation, with metabolites eliminated primarily via the renal route. Steady-state concentrations are achieved after 4 to 5 weeks of consistent dosing, and it demonstrates linear pharmacokinetics within the therapeutic range.

Contra-indications

• Hypersensitivity to tirzepatide or any component of the formulation
• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2

Adverse effects

• Nausea
• Vomiting
• Diarrhoea
• Constipation
• Decreased appetite
• Abdominal pain
• Injection site reactions
• Pancreatitis

Interactions

• May enhance the effects of other antidiabetic medications
• Caution advised with medications that affect gastrointestinal motility

Precautions

• Monitor for signs of pancreatitis
• Consider risk of hypoglycemia when used with insulin or sulfonylureas
• Assess renal function prior to initiation and during treatment
• Evaluate for gallbladder disease prior to treatment

Pregnancy

There are no adequate and well-controlled studies in pregnant women. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether tirzepatide is excreted in human milk. Caution is advised when administering to nursing women.

Storage

Store in the refrigerator (2°C to 8°C). Do not freeze. Once in use, may be stored at room temperature (up to 30°C) for up to 21 days.

Formulations

• Subcutaneous injection solution